Seagen Inc
F:SGT
Fundamental Analysis
Seagen’s heavy dependence on a few key drugs, such as Adcetris and Padcev, poses a significant revenue concentration risk if clinical setbacks or patent challenges reduce sales or slow adoption.
Seagen’s established leadership in ADC technology, underscored by the commercial success of Adcetris and Padcev, positions it to remain a frontrunner in next-generation oncology treatments.

Revenue & Expenses Breakdown
Seagen Inc
Balance Sheet Decomposition
Seagen Inc
Current Assets | 2.6B |
Cash & Short-Term Investments | 1.2B |
Receivables | 631.6m |
Other Current Assets | 683m |
Non-Current Assets | 1.1B |
PP&E | 487.7m |
Intangibles | 495m |
Other Non-Current Assets | 100m |
Free Cash Flow Analysis
Seagen Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Seagen Inc
Revenue
|
2.3B
USD
|
Cost of Revenue
|
-566.1m
USD
|
Gross Profit
|
1.7B
USD
|
Operating Expenses
|
-2.5B
USD
|
Operating Income
|
-750.5m
USD
|
Other Expenses
|
300k
USD
|
Net Income
|
-750.2m
USD
|
SGT Profitability Score
Profitability Due Diligence
Seagen Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Seagen Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
SGT Solvency Score
Solvency Due Diligence
Seagen Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Seagen Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGT Price Targets Summary
Seagen Inc
Dividends
Current shareholder yield for SGT is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?